Hostname: page-component-8448b6f56d-wq2xx Total loading time: 0 Render date: 2024-04-16T23:42:12.073Z Has data issue: false hasContentIssue false

Risk of fatal adverse events associated with 17DD yellow fever vaccine

Published online by Cambridge University Press:  08 November 2004

C. J. STRUCHINER
Affiliation:
Programa de Computação Científica, Fundação Oswaldo Cruz, Av. Brasil 4365, Manguinhos, Rio de Janeiro, RJ, Brasil, CEP 21045-900
P. M. LUZ
Affiliation:
Programa de Computação Científica, Fundação Oswaldo Cruz, Av. Brasil 4365, Manguinhos, Rio de Janeiro, RJ, Brasil, CEP 21045-900
I. DOURADO
Affiliation:
Instituto de Saúde Coletiva, Universidade Federal da Bahia, Salvador, Bahia, Brasil
H. K. SATO
Affiliation:
Secretaria de Saúde do Estado de São Paulo, São Paulo, SP, Brasil
S. G. AGUIAR
Affiliation:
Biomanguinhos, Fundação Oswaldo Cruz, Av. Brasil 4365, Manguinhos, Rio de Janeiro, RJ, Brasil, CEP 21045-900
J. G. L. RIBEIRO
Affiliation:
Secretaria de Saúde do Estado de Minas Gerais, Belo Horizonte, MG, Brasil
R. C. R. SOARES
Affiliation:
Programa Nacional de Imunizações, Fundação Nacional de Saúde, Brasília, DF, Brasil
C. T. CODEÇO
Affiliation:
Programa de Computação Científica, Fundação Oswaldo Cruz, Av. Brasil 4365, Manguinhos, Rio de Janeiro, RJ, Brasil, CEP 21045-900
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Yellow fever (YF), an acute infectious disease, is endemic in the north and central-west of Brazil. This disease can be prevented by the use of a vaccine. In Brazil, four fatal adverse events have been associated with the YF vaccine used in the country (17DD vaccine). We briefly describe the last two fatalities, and estimate the risk of 17DD-associated fatal adverse events under different epidemiological scenarios. Controversies regarding the appropriate denominator that enters the estimation of risk serve as a motivation for each proposed scenario. The statistical procedures used show optimum behaviour when assessing the risk of rare events. Risk estimates vary from 0·043 (95% CI 0·017–0·110) to 2·131 (95% CI 0·109–12·071) fatalities per million doses administered. The robust estimates of the risk of fatal adverse events we present constitute an important element in future risk–benefit analysis and point to the need for good quality vaccine coverage and adverse-events surveillance data to assess the risk of vaccination. Although vaccination of YF endemic regions is necessary to maintain low disease prevalence, preventive administration of YF vaccine to the entire population should be cautiously analysed.

Type
Research Article
Copyright
© 2004 Cambridge University Press